文献速递淋巴瘤

侵袭性淋巴瘤合并肝功能不全患者的多柔比星药代动力学与毒性

Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment.
PubMed 文献 · Blood Adv · 2023-01-01

在59例胆红素正常和10例胆红素升高的侵袭性淋巴瘤患者中,评估全剂量EPOCH±利妥昔单抗方案下多柔比星及其代谢物多柔比星醇的药代动力学与毒性。胆红素升高组多柔比星清除率中位数较低、血浆浓度中位数较高,但均在正常组浓度范围内;第一周期毒性更大但可安全管理。结果表明胆红素升高患者可能无需经验性减量持续输注多柔比星。

要点

  • 胆红素升高组多柔比星清除率中位数较低、浓度中位数较高,但均在正常组范围内。
  • 第一周期胆红素升高组4级中性粒细胞减少和血小板减少更多,后续周期无差异。
  • 第一周期胆红素升高组3/4级胃肠道和神经毒性更多,但不良事件可安全管理。

核心结论

  • 胆红素升高患者经验性减量持续输注多柔比星可能并非必要。

研究设计与样本

  • 研究纳入59例胆红素正常和10例胆红素升高的侵袭性淋巴瘤患者,接受全剂量EPOCH±利妥昔单抗治疗。
  • 中位(范围)年龄为51(18-75)岁。
  • 试验注册号为NCT00001337、NCT00069238和NCT00005780。

主要发现

  • 胆红素升高组国际预后指数更高、体能状态更差。
  • 胆红素升高组多柔比星清除率中位数较低,血浆多柔比星和多柔比星醇浓度中位数较高,但均在正常组浓度范围内。
  • 两组发热性中性粒细胞减少发生率相似。
  • 第一周期胆红素升高组4级中性粒细胞减少和血小板减少更多,后续周期无差异。
  • 第一周期胆红素升高组3/4级胃肠道和神经毒性更多,后续周期无差异。

临床怎么用

  • 作者认为胆红素升高患者经验性减量持续输注多柔比星可能并非必要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aggressive lymphomas are curable with doxorubicin-based chemotherapy. In patients presenting with elevated serum bilirubin, doxorubicin is commonly dose reduced or delayed based on limited pharmacokinetic data. We evaluated plasma pharmacokinetics of doxorubicin and its metabolite doxorubicinol as well as toxicity in 59 patients with normal bilirubin levels and 10 patients with elevated bilirubin levels. Patients received full-dose EPOCH +/-rituximab. Median (range) age was 51 (18-75) years. Patients with elevated bilirubin levels had higher international prognostic index and poorer performance status. Although median doxorubicin clearance was lower and median plasma doxorubicin and doxorubicinol concentrations were higher in patients with elevated bilirubin levels, values were within the concentration range observed in patients with normal levels. Rates of febrile neutropenia were similar between groups, but there was greater grade 4 neutropenia and thrombocytopenia during the first but not subsequent treatment cycles in patients with elevated bilirubin. More grade 3/4 gastrointestinal and neurotoxicity occurred in patients with elevated bilirubin during the first but not subsequent cycles. Although toxicity was greater on cycle 1, the adverse effects were managed safely. These results show that empiric dose reductions of continuous infusion doxorubicin may not be necessary in patients with elevated bilirubin levels. This trial was registered at www.clinicaltrials.gov as #NCT00001337, #NCT00069238, and #NCT00005780.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lai C, Cole DE, Steinberg SM, et al. Doxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment. Blood Adv. 2023. PMID: 35882475. doi:10.1182/bloodadvances.2022007431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。